Why Alcobra (ADHD) Stock Is Declining Today

NEW YORK (TheStreet) -- Alcobra (ADHD) shares are down -2.81% to $20.03 on Wednesday after having coverage initiated with a "market perform" rating and $23 price target by analysts at FBR Capital Markets.

The Israel-based biopharmaceutical company is in the process of developing a drug treatment for Attention Deficit Hyperactivity Disorder.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

 

ADHD Chart ADHD data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

If you liked this article you might like

Johnson & Johnson Shuts Insulin Pump Business, Inks Other Deals

Johnson & Johnson Shuts Insulin Pump Business, Inks Other Deals

Alcobra Shares Plummet as ADHD Drug Fails

Alcobra Shares Plummet as ADHD Drug Fails

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Alcobra (ADHD) Stock Sliding, Downgraded After FDA Clinical Hold

Alcobra (ADHD) Stock Sliding, Downgraded After FDA Clinical Hold

Alcobra (ADHD) Stock Tumbles on FDA Clinical Hold, Cantor Remains Bullish

Alcobra (ADHD) Stock Tumbles on FDA Clinical Hold, Cantor Remains Bullish